Investment bank: Estimates too high ahead of Genmab's annual report
Genmab’s earnings forecast for 2024 will probably be somewhat lower than the consensus gathered by Genmab itself, says JPMorgan in a prelude to the financial report on Feb. 14.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.